La Jolla Pharmaceutical (LJPC) Reports GCS-100 Shows Efficacy in Phase 2
Tweet Send to a Friend
La Jolla Pharmaceutical (NASDAQ: LJPC) announced that an abstract of the results for the Company’s Phase 2 clinical trial of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE